Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atovaquone in Platinum-Resistant Ovarian Cancer
NCT05998135Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Nov 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atovaquone in ovarian cancer, sponsored by Emory University. Primary endpoint: Progression-Free Survival at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
atovaquone
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05998135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998135.